Dendritic Cell Preparation with PD-L1 Blockade and CD40 Agonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dendritic cell preparation methods face challenges such as low cell yield, poor viability, limited T cell activation, and inconsistent culture conditions, leading to insufficient antigen presentation and reduced immune response efficacy.
Innovation Solution
A novel dendritic cell preparation method involving PD-L1 negative dendritic cells and/or dendritic cells with CD40 agonists bound to the cell surface, with specific proportions and enhanced by PD-L1 antibodies and CD40 agonists to improve maturity and antigen presentation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If dendritic cells are isolated from peripheral blood, then antigen presenting cells are obtained, but cell yield is low and isolation is time-consuming and labor-intensive
Solution Approach 1:
The patent applies preliminary action by inducing and culturing dendritic cells in vitro from monocyte precursors before they are needed for therapy. This allows large quantities of dendritic cells to be produced in advance through controlled culture conditions, eliminating the time-consuming and labor-intensive process of isolating them directly from peripheral blood at the time of treatment.
2Quantity of substance
If dendritic cells are cultured in vitro, then cell quantity increases, but cell viability decreases and activation is insufficient
Solution Approach 1:
The patent applies parameter changes by optimizing culture conditions including specific cytokine concentrations (GM-CSF, IL-4, TNF-α), pH levels, and temperature to maintain high cell viability during in vitro expansion. The culture system uses controlled parameter adjustments to prevent cell death and maintain functional integrity throughout the culture period.
Solution Approach 2:
The patent uses cytokines as intermediary substances to maintain dendritic cell viability and promote their maturation during culture. Specific cytokines (GM-CSF, IL-4, TNF-α) act as mediators that support cell survival, prevent apoptosis, and drive differentiation, thereby maintaining high viability rates throughout the in vitro expansion process.
3Ease of manufacture
If dendritic cells are cultured using standard protocols, then culture process is established, but T cell activation capability is limited and antigen presentation is insufficient
Solution Approach 1:
The patent applies dynamics by implementing a multi-stage culture process that dynamically adjusts conditions at different time points. The culture progresses through distinct phases (differentiation, maturation, activation) with changing cytokine profiles and environmental parameters, allowing dendritic cells to develop progressively enhanced T cell activation capabilities while maintaining ease of manufacture through standardized stage transitions.
Solution Approach 2:
The patent uses composite culture systems combining multiple cytokines (GM-CSF, IL-4, TNF-α) and signaling molecules that work synergistically to enhance dendritic cell function. This composite approach creates a more potent immunostimulatory environment than single-factor cultures, improving T cell activation capability while maintaining a manageable culture process.
4Adaptability or versatility
If dendritic cells express PD-L1 on surface, then immune regulation occurs, but T cell activation is inhibited and functional defects occur
Solution Approach 1:
The patent applies the taking out principle by selectively removing or suppressing PD-L1 expression on dendritic cell surfaces through targeted interventions during culture. This extraction of the inhibitory PD-L1 molecule eliminates the brake on T cell activation while preserving other important immune regulatory functions, thereby resolving the contradiction between regulation and activation.
Solution Approach 2:
The patent applies preliminary anti-action by pre-treating dendritic cells with agents that block PD-L1 function or reduce its expression before the cells are used for T cell activation. This preliminary counter-measure against PD-L1-mediated inhibition ensures that when dendritic cells encounter T cells, the activation pathway is not blocked, while other immune regulatory mechanisms remain intact.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly enhances dendritic cell activation and T cell amplification, improving antigen-specific T lymphocyte recognition and elimination of cancer cells, demonstrating high clinical safety and efficacy in cancer treatment and prevention.
Implementation Method 1
PD-L1 molecules bind to the B7.1 molecule of dendritic cells... PD-L1 antibody... blocks the PD-L1 molecules on the surface of dendritic cells
Implementation Method 2
CD40 is a co-stimulatory factor and protein receptor present on antigen presenting cells (APCs)... CD40 binding to CD154 (also known as CD40L) on helper T cells, antigen presenting cells are activated
Data Source
AI summary
The present application discloses a novel dendritic cell preparation and a preparation method thereof. The cell preparation comprises PD-L1 negative dendritic cells and/or dendritic cells with CD40 agonists bound to the cell surface. The preparation method comprises: blocking and/or activating dendritic cells with a treatment agent, wherein the treatment agent comprises PD-L1 antibodies and/or CD40 agonists. The specific method includes adding the treatment agent to block and/or activate dendritic cells either during the dendritic cell culture stage or after completion of the culture. The dendritic cell preparation provided by the present application has enhanced maturity, improved antigen presentation, and a superior capacity to activate and amplify antigen-specific T cells compared to conventional dendritic cells, and has broad application prospects in the field of cancer immunotherapy.